🧬 Amylin & GLP-1: Double Agents for Weight Loss & DM-CagriSema (Part II)
Dr RR Baliga's "Got Knowledge Doc" Podkast
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
🚨 Major breakthrough in obesity pharmacotherapy!
The REDEFINE-1 & REDEFINE-2 trials show that once-weekly CagriSema (Cagrilintide + Semaglutide) delivers up to 20% weight loss in people with obesity—and significant glycemic improvements in those with type 2 diabetes. 💉📉
🌍 Global, double-blind RCTs
⚖️ >90% lost ≥5% body weight
🩺 SBP ↓, QoL ↑, prediabetes reversed in 88%
⚠️ GI side effects common but mostly mild
💡 CagriSema is redefining the weight loss frontier—with dual satiety and metabolic action.
#Obesity #GLP1 #Cagrilintide #Semaglutide #CagriSema #WeightLoss #RCT #MetabolicHealth #Prediabetes #NovoNordisk #Endocrinology #InternalMedicine #PrecisionMedicine #Pharma #ClinicalTrials #ObesityMedicine #Amylin #GLP1Agonist #T2D #LifestyleMedicine